Clinical trials in Scarborough, ME

21 recruiting studies have a site in or near Scarborough, ME, Maine.

Top conditions here

All conditions

Showing 21 of 21 studies

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Augusta, ME · Bangor, ME · Belfast, ME · +1147 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Scarborough, ME · +114 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Augusta, ME · Scarborough, ME · South Portland, ME · +278 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Portland, ME · Scarborough, ME · South Portland, ME · +172 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Brunswick, ME · Portland, ME · +222 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Brunswick, ME · Portland, ME · +132 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Scarborough, ME · +52 more sites

RecruitingPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Sponsor: SWOG Cancer Research Network

Bath, ME · Brewer, ME · Portland, ME · +331 more sites

RecruitingPhase not listedNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Sponsor: Alliance for Clinical Trials in Oncology

Augusta, ME · Belfast, ME · Biddeford, ME · +744 more sites

RecruitingNot applicableNCT07283939

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Sponsor: Alliance for Clinical Trials in Oncology

Brunswick, ME · Damariscotta, ME · Sanford, ME · +357 more sites

RecruitingPhase 2NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sponsor: Alliance for Clinical Trials in Oncology

Bath, ME · Brunswick, ME · Portland, ME · +108 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Scarborough, ME · +43 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Bangor, ME · Scarborough, ME · +184 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Augusta, ME · Belfast, ME · Biddeford, ME · +1223 more sites

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Bangor, ME · Scarborough, ME · +162 more sites

RecruitingPhase 3NCT04423211

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Sponsor: ECOG-ACRIN Cancer Research Group

Bath, ME · Biddeford, ME · Portland, ME · +338 more sites

RecruitingPhase not listedNCT04398628

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Sponsor: American Thrombosis and Hemostasis Network

Scarborough, ME · +75 more sites

RecruitingPhase 3NCT06801834

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Sponsor: Gilead Sciences

Scarborough, ME · +22 more sites

RecruitingPhase not listedNCT01790152

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Sponsor: Children's Oncology Group

Scarborough, ME · +68 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Augusta, ME · Bangor, ME · Belfast, ME · +1226 more sites

RecruitingPhase 2NCT06333262

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Sponsor: Inhye Ahn

Scarborough, ME · +3 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.